{
    "body": "Which enzyme is inhibited by ixazomib?", 
    "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/27119237", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26667773", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27121262", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26846321", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25377318", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26988986", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25919767", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26558304", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26658418", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26138345", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26588946", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26709701", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27783987", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27325500", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26141494", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23514361", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26872892", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27261328", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26337806", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25234165", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27702799", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25456369", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26811670", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26634271", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27259216", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25302026", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26947893"
    ], 
    "ideal_answer": [
        "Ixazomib is proteasome inhibitor. It is used for treatment of multiple myeloma."
    ], 
    "exact_answer": [
        "proteasome"
    ], 
    "concepts": [
        "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D004791"
    ], 
    "type": "factoid", 
    "id": "589630f378275d0c4a000007", 
    "snippets": [
        {
            "offsetInBeginSection": 144, 
            "offsetInEndSection": 492, 
            "text": "Over the past decade, MM therapy is significantly improved by the introduction of novel therapeutics such as immunomodulatory agents (thalidomide, lenalidomide, and pomalidomide), proteasome inhibitors (bortezomib, carfilzomib, and ixazomib), monoclonal antibodies (daratumumab and elotuzumab), histone deacetylase (HDAC) inhibitors (Panobinostat).", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/27261328", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 296, 
            "offsetInEndSection": 516, 
            "text": "Due to the largely incurable nature of multiple myeloma, the development of newer agents is ongoing and includes new oral PIs (ixazomib), immunotherapies (e.g., CD38- or SLAMF7-targeted antibodies), and small molecules. ", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/26558304", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 211, 
            "offsetInEndSection": 394, 
            "text": "Ixazomib (MLN9708-MLN2238), the second-generation proteasome inhibitor, selectivity and potency were similar to that of bortezomib, is currently being investigated in phase I studies.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/26667773", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 229, 
            "text": "In the last few weeks, the FDA approved three new therapies for multiple myeloma: ixazomib, the first oral proteasome inhibitor; and daratumumab and elotuzumab, two monoclonal antibodies that target CD38 and SLAMF7, respectively.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/26658418", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 289, 
            "offsetInEndSection": 551, 
            "text": "Ixazomib, the first oral proteasome inhibitor to be evaluated in multiple myeloma, exerts substantial anti-myeloma activity as a single agent and particularly in combination with immunomodulatory drugs and it may be an attractive option for maintenance therapy. ", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/26588946", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 710, 
            "offsetInEndSection": 893, 
            "text": "Since the introduction of bortezomib in 2003, several next-generation proteasome inhibitors have also been used clinically, including carfilzomib, oprozomib, ixazomib, and delanzomib.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/26947893", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 229, 
            "text": "AIM: The aim of the present study was to characterize the pharmacokinetics of the oral proteasome inhibitor, ixazomib, in patients with solid tumours and moderate or severe hepatic impairment, to provide posology recommendations.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/27121262", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 128, 
            "text": "Pharmacokinetics of ixazomib, an oral proteasome inhibitor, in solid tumour patients with moderate or severe hepatic impairment.", 
            "beginSection": "title", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/27121262", 
            "endSection": "title"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 75, 
            "text": "Ixazomib is the first oral, proteasome inhibitor to reach phase III trials.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/26141494", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 233, 
            "offsetInEndSection": 350, 
            "text": "MLN2238 (ixazomib), an oral proteasome inhibitor, has improved pharmacotherapeutic parameters compared to bortezomib.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/27783987", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 256, 
            "text": "This population pharmacokinetic analysis of the investigational oral proteasome inhibitor ixazomib assessed the feasibility of switching from body surface area (BSA)-based to fixed dosing, and the impact of baseline covariates on ixazomib pharmacokinetics.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/25377318", 
            "endSection": "abstract"
        }
    ]
}